• Roivant reported a JAMA Dermatology publication of skin-focused Phase 3 VALOR results for brepocitinib in adult dermatomyositis.
• Findings were already presented in a prior New England Journal of Medicine paper, with this report detailing additional skin-specific outcomes.
• Brepocitinib delivered faster, more durable improvements in skin symptoms and itch than placebo, with more patients reaching remission-level skin outcomes.
• Results also supported meaningful steroid tapering, strengthening the drug’s positioning as a potential new oral option for dermatomyositis.
• Safety signals were consistent with JAK inhibitors, with more serious infections on brepocitinib versus placebo in the trial.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Roivant Sciences Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608261111PRIMZONEFULLFEED9816540) on August 26, 2026, and is solely responsible for the information contained therein.